His₆-Tagged Endoglycosidase H for N-linked Glycan Removal

A Reliable Tool for Structural Biology & Protein Engineering

MinneBio Endoglycosidase H (Endo H) is a highly active recombinant glycosidase designed for precise removal of high-mannose/hybrid N-linked glycans from glycoproteins. By specifically cleaving the chitobiose core of susceptible N-glycans while leaving a single GlcNAc residue attached to the protein, Endo H enables detailed analysis of glycosylation patterns, protein maturation, and glycoprotein quality. Ideal for structural biology, biopharmaceutical research, and protein characterization workflows, MinneBio Endo H provides reliable and consistent performance for both analytical and preparative applications.

1. Upper Left Image: Purified MinneBio His₆-Tagged Endoglycosidase H (Endo H)

SDS-PAGE analysis demonstrates the high purity and consistent quality of recombinant MinneBio His₆-Tagged Endoglycosidase H (Endo H), supporting reliable performance for precise glycoprotein processing applications.

2. Upper Right Image: Efficient Cleavage of High-Mannose/Hybrid N-Linked Glycans by MinneBio His₆-Tagged Endoglycosidase H (Endo H)

Following incubation with MinneBio His₆-Tagged Endoglycosidase H for 1 hour at 37°C, RNase B was efficiently converted to RNase A, demonstrating the enzyme’s high specificity and activity under optimized cleavage conditions. This result confirms efficient removal of high-mannose/hybrid N-linked glycans while maintaining the integrity of the target protein.

3. Lower Image: Specific Recognition and Cleavage Mechanism

MinneBio His₆-Tagged Endoglycosidase H specifically recognizes and cleaves Endo H-sensitive N-linked glycans, enabling efficient deglycosylation and generation of native-like recombinant proteins for structural and functional studies.

SHARE

Related Post

AGENTEX: A New Synthetic Biology Platform Expanding the Possibilities of Protein Engineering

Researchers in Professor George Church’s laboratory at Harvard Medical School, in collaboration...

Engineering New Druggable Surface

On August 26, 2026, the FDA approved Rasonque (daraxonrasib) for adults with...

Personalized mRNA Therapeutic Cancer Vaccines: A New Chapter in Oncology

After mRNA vaccines achieved remarkable success during the COVID-19 pandemic a few...